A recent report from the UK Bioindustry Association (BIA), sets out how the UK life sciences sector is driving investment and growth, making the case for increased cost-effective public investment in the sector.

The aim of the report is to inform the UK Government, UK Research and Innovation (UKRI), and other policymakers as they prepare for the forthcoming Spending Review and develop an R&D roadmap to reach the target of raising R&D investment to 2.4% of GDP by 2027.

BioAscent features in the report as a case study example of an innovative life sciences business that has received innovation support from the Medicines Discovery Catapult.

To read the report, which was published in June 2019, click here.